Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center
global study. The primary end point is 75% improvement from baseline according to the
Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and
safety at a dosage of 50mg subcutaneous (Sc) twice weekly.

Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center
global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance.

Inclusion Criteria:

- Male or female adults

- PsO diagnosis for 6 months

- Active disease: PASI greater than or equal to 12, Physician's Static Global
Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5),

- Body Surface Area (BSA) involved with PsO greater than or equal to 10%

- Dermatology Life Quality Index (DQLI) greater than or equal to 10

- Previously received phototherapy or systemic non-biologic therapy for PsO

Exclusion Criteria:

- Forms of Psoriasis other than PsO

- Drug induced Psoriasis

- Positive QuantiFERON-tuberculosis (TB) Gold Test

- Presence of significant comorbid conditions

- Chemistry and hematology values outside protocol specified range

- Major systemic infections